BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

What Makes Regeneron Pharmaceuticals, Inc. (REGN)'s R&D Exec a Top Earner in Biotech?


1/11/2013 10:25:07 AM

As biotech R&D spending grows, and a steady stream of biotech products continues to win regulatory approval, R&D executives at the companies commercializing these drugs has been rising accordingly. In a new analysis published in Nature Biotechnology, Senior Editor Michael Francisco looks at the salaries of the top-paid biotech R&D officers, as reported in the 2013 BioWorld Executive Compensation Report. The report tracks the annual compensation for biopharmaceutical execs at 258 companies based on U.S. Securities and Exchange Commission filings. In his analysis, Francisco notes that in addition to salary and bonuses, other compensation like stock, stock options and long-term cash awards can double total compensation for R&D officers at these big companies. The top five earners, ranked by total compensation, in 2011 were: George Yancopoulos, founding scientist, president and chief scientific officer, Regeneron Pharmaceuticals, $2.6 million (salary = $653,000) Roger Perlmutter, former executive vice president of research & development, Amgen, $2.4 million (salary = $982,000) Norbert Bischofberger, executive vice president of research & development and chief scientific officer, Gilead Sciences, $1.6 million (salary = $756,000) Stephen P. Squinto, executive vice president and head of R&D, Alexion Pharmaceuticals, $1.33 million (salary = $475,000) Douglas Williams, executive vice president of R&D, Biogen Idec, $1.3 million (salary = $594,000)

Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->